MSI 94

Drug Profile

MSI 94

Latest Information Update: 08 Aug 2007

Price : $50

At a glance

  • Originator Genaera Corporation
  • Class Antibacterials; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Skin and soft tissue infections

Most Recent Events

  • 08 Jun 2001 No-Development-Reported for Skin and soft tissue infections in USA (Topical)
  • 28 Mar 2001 Magainin Pharmaceuticals is now called Genaera Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top